Related Experiment Video
Updated: Dec 4, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Autocrine motility factor and its receptor expression in musculoskeletal tumors
Kosei Nakajima1,2, Avraham Raz3
1Division of Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo 104-0045, Japan.
Abstract:
Management of aggressive malignant musculoskeletal tumors is clinically challenging and awaits the identification of regulator(s) that can be therapeutically used to improve patient outcome. Autocrine motility factor (AMF), a secreted cytokine, is known to alter the bone microenvironment by linking to its receptor AMFR (AMF Receptor), leading to tumor progression. It was noted that both the ligand and its receptor belong to the moonlighting family of proteins, as they contribute to intracellular metabolic function such as glycolysis and gluconeogenesis by expressing glucose-6-phosphate isomerase AMF/GPI and higher protein degradation by expressing AMFR/gp78 functioning as ubiquitin ligase activity. Thus, AMF/GPI and AMFR/gp78 contribute to higher metabolic turnover of protein and glucose. Recently, a large-scale cohort study including 23 different histological types of musculoskeletal tumors revealed that patients with osteosarcoma, multiple myeloma, rhabdomyosarcoma, and angiosarcoma tend to express higher levels of AMF, whereas multiple myeloma patients expressed high levels of AMFR. Consistently, the cellular data showed that a variety of musculoskeletal tumors express AMF and components of bone microenvironment express AMFR. Thus, a novel outlook suggests a cellular link and cross-talk between musculoskeletal tumors and the skeletal milieu are regulated by AMF-AMFR signaling. This review will highlight the pharmacological need for AMF and AMFR inhibitors as unmet medical needs for patients with malignant musculoskeletal tumors.
Insights
Autocrine motility factor (AMF) and its receptor (AMFR) signaling drives aggressive musculoskeletal tumors. Inhibiting AMF and AMFR presents a potential therapeutic strategy for these challenging cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Aggressive malignant musculoskeletal tumors pose significant clinical challenges.
- Autocrine motility factor (AMF) and its receptor (AMFR) signaling are implicated in tumor progression by altering the bone microenvironment.
- AMF/GPI and AMFR/gp78 are moonlighting proteins involved in cellular metabolism and protein degradation, contributing to increased metabolic turnover.
Purpose of the Study:
- To review the role of AMF-AMFR signaling in malignant musculoskeletal tumors.
- To highlight the potential of targeting AMF and AMFR as a therapeutic strategy.
- To underscore the unmet medical need for novel treatments in this area.
Main Methods:
- Literature review of studies on AMF and AMFR in musculoskeletal tumors.
- Analysis of a large-scale cohort study examining AMF and AMFR expression in various tumor types.
- Examination of cellular data linking tumor cells and bone microenvironment components via AMF-AMFR signaling.
Main Results:
- Musculoskeletal tumors, including osteosarcoma and multiple myeloma, show elevated AMF expression.
- Multiple myeloma patients exhibit high AMFR expression.
- Cellular data confirms AMF expression in tumors and AMFR expression in the bone microenvironment, indicating cross-talk.
Conclusions:
- AMF-AMFR signaling represents a critical link between musculoskeletal tumors and the skeletal environment.
- Pharmacological inhibition of AMF and AMFR is a promising therapeutic avenue.
- Targeting this pathway addresses a significant unmet medical need in managing aggressive malignant musculoskeletal tumors.
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Role of Myosin in Cell Migration
Myosin II is a hexamer comprising two heavy chains with globular heads and coiled-coil tails, two regulatory light chains, and two essential light chains. The ATPase sites on the myosin heads hydrolyze ATP, and the released phosphate generates the force for contraction....
Satellite Stem Cells and Muscular Dystrophy
Cytoskeletal Coordination in Cell Migration
Microtubules in Cell Motility

